Concepedia

Author

Sarah Arbe‐Barnes

Medicines for Malaria VentureORCID

Also Known As

Sarah Arbe-Barnes, Sarah Arbe‐Barnes, Sarah J Arbe-Barnes

22

Publications

1.7K

Citations

12

H-Index

21

Concepts

All Affiliations

Medicines for Malaria VentureShin Poong Pharm (South Korea)Swiss Tropical and Public Health InstituteStevenage Bioscience CatalystAptiv (United Kingdom)
SA

About

Sarah Arbe‐Barnes is an author at Medicines for Malaria Venture specializing in medicine, drug resistance, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

1.2K

2

Pharmacology

3

3

1K

3

Health Sciences

1

1

21

4

Immunology

1

1

374

5

Neurology

1

1

183

Sarah Arbe‐Barnes

×

13

Publications

1.7K

Citations

12

H-Index

YearCitations

Identification of an antimalarial synthetic trioxolane drug development candidate

Jonathan L. Vennerstrom, Sarah Arbe‐Barnes, Reto Brun,

Nature

2004

613

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

Susan A. Charman, Sarah Arbe‐Barnes, Ian Bathurst,

Proceedings of the National Academy of Sciences

2011

374

Stroke Treatment Academic Industry Roundtable X

Sean I. Savitz, Jean‐Claude Baron, Marc Fisher,

Stroke

2019

183

Review of pyronaridine anti-malarial properties and product characteristics

Simon L. Croft, Stephan Duparc, Sarah Arbe‐Barnes,

Malaria Journal

2012

154

First‐in‐man safety and pharmacokinetics of synthetic ozonide <scp>OZ439</scp> demonstrates an improved exposure profile relative to other peroxide antimalarials

Joerg J. Moehrle, Stephan Duparc, Christoph Siethoff,

British Journal of Clinical Pharmacology

2012

115

Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials

Stephan Duparc, Isabelle Borghini-Fuhrer, Carl J Craft,

Malaria Journal

2013

87

Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study

Gaston Tona Lutete, Ghyslain Mombo‐Ngoma, Serge-Brice Assi,

PLoS Medicine

2021

46

A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy

Guillermo Garcia‐Manero, Elias Jabbour, Marina Konopleva,

Blood

2018

34

A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy

Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Hui Yang,

Blood

2016

23

Plasmodium vivax: In vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75

Clemens H. M. Kocken, Annemarie Voorberg-van der Wel, Sarah Arbe‐Barnes,

Experimental Parasitology

2006

21

Page 1